HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research report sent to investors on Tuesday morning, The Fly reports. The brokerage currently has a $82.00 price objective on the stock, up from their previous price objective of $72.00.

GTHX has been the topic of several other reports. Cowen reissued a buy rating on shares of G1 Therapeutics in a research note on Thursday, December 12th. BTIG Research increased their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a buy rating in a research note on Tuesday, January 7th. ValuEngine upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a report on Friday, December 27th. BidaskClub downgraded shares of G1 Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 8th. Finally, Zacks Investment Research lowered shares of G1 Therapeutics from a hold rating to a sell rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $61.43.

Shares of NASDAQ GTHX traded down $0.25 during midday trading on Tuesday, reaching $24.45. The stock had a trading volume of 2,063 shares, compared to its average volume of 233,561. The firm has a market cap of $953.07 million, a price-to-earnings ratio of -8.20 and a beta of 2.23. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $41.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 14.28 and a current ratio of 14.28. The company’s 50 day moving average price is $25.83 and its 200 day moving average price is $27.25.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.86) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.01. Equities analysts forecast that G1 Therapeutics will post -3.29 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can lifted its position in G1 Therapeutics by 93,600.0% in the 2nd quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $86,000 after acquiring an additional 2,808 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in G1 Therapeutics by 18.8% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,166 shares of the company’s stock worth $97,000 after acquiring an additional 500 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in G1 Therapeutics during the 2nd quarter worth $235,000. Metropolitan Life Insurance Co NY lifted its position in shares of G1 Therapeutics by 51.3% during the third quarter. Metropolitan Life Insurance Co NY now owns 11,600 shares of the company’s stock valued at $264,000 after purchasing an additional 3,935 shares in the last quarter. Finally, Parametric Portfolio Associates LLC purchased a new position in G1 Therapeutics during the second quarter worth about $406,000. Institutional investors own 77.25% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Featured Article: Roth IRA

The Fly

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.